Arecoline inhibits catecholamine release from perfused rat adrenal gland

Acta Pharmacologica Sinica

Volumn 27, Issue 1, 2006, Pages 71-79

  Lim, Dong Yoon ^a   Kim, Il Sik ^a  

^a Chosun University   (South Korea)

Author keywords

Adrenal gland; Arecoline; Catecholamine secretion; Nicotine

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM; 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; [4 [(3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYL]TRIMETHYLAMMONIUM; ACETYLCHOLINE; ADENOSINE TRIPHOSPHATASE; ARECOLINE; BICARBONATE; CALCIUM CHANNEL L TYPE; CATECHOLAMINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYCLOPIAZONIC ACID; NICOTINE; PILOCARPINE; POTASSIUM ION;

ADRENAL GLAND; ANIMAL TISSUE; ARTICLE; BETEL NUT; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CATECHOLAMINE RELEASE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; FLUOROMETRY; MALE; MEMBRANE DEPOLARIZATION; NONHUMAN; RAT; RECEPTOR UPREGULATION;

(4-(M-CHLOROPHENYLCARBAMOYLOXY)-2-BUTYNYL)TRIMETHYLAMMONIUM CHLORIDE; 3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ACETYLCHOLINE; ADRENAL GLANDS; ANIMALS; ARECOLINE; CALCIUM CHANNEL AGONISTS; CALCIUM-TRANSPORTING ATPASES; CATECHOLAMINES; CHOLINERGIC AGONISTS; DIMETHYLPHENYLPIPERAZINIUM IODIDE; INDOLES; MALE; NICOTINE; NICOTINIC AGONISTS; PERFUSION; RATS;

EID: 30144438899     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00233.x     Document Type: Article

References (35)

1. International Agency for Research on Cancer. Betel-quid and areca-nut chewing. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Volume 37. Lyon: IARC; 1985. p 141-202.
2. Mujumder AM, Kapadi AH, Pendse GS. Chemistry and pharmacology of betel nut Areca catechu Linn. J Plant Crops 1979; 7: 69-92.
3. Holdsworth DK, Jones RA, Self R. Volatile alkaloids from Areca catechu. Phytochemistry 1998; 48: 581-2.
4. Bhonsle RB, Murti PR, Gupta PC. Tobacco habits in India. In: Gupta PC, Hamner JE, Murti PR, editors. Control of tobacco-related cancers and other diseases. Bombay: Oxford University Press; 1992. p 25-6.
5. Molinengo L, Fundaro AM, Cassone MC. Action of a chronic arecoline administration on mouse motility and on acetylcholine concentrations in CNS. J Pharm Pharmacol 1988; 40: 821-2.
6. Taylor RF, Al-Jarad N, John LM, Conroy DM, Barnes NC. Betel-nut chewing and asthma. Lancet 1992; 339: 1134-6.
7. Trimarchi GR, Germano A, Campo GM, De Luca R, Caputi AP. Changes in urine volume and urinary electrolyte excretion after intracerebroventricular injection of arecoline and hemicholinium-3. Life Sci 1991; 48: 2097-107.
8. Mondadore C, Hengerer B, Ducret T, Borkowski J. Delayed emergence of effects of memory-enhancing drugs: implication for dynamics of long-term potentiation. Proc Natl Acad Sci USA 1994; 91: 2041-5.
9. Raffaele KC, Berardi A, Asthana S, Morris P, Haxby JV, Soncrant TT. Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type. Psychopharmacol Bull 1991; 27: 315-9.
10. Carey GJ, Costall B, Domeney AM, Gerald PA, Jones DN, Naylor RJ, et al. Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset. Pharmacol Biochem Behav 1992; 42: 75-83.
11. Riekkinen P Jr, Ridkkinen M, Sirvil J. Cholinergic drugs regulate passive avoidance performance via the amygdala. J Pharmacol Exp Ther 1993; 267: 1484-92.
12. Fisher SK, Bartus RT. Regional differences in the coupling of muscarinic receptors to inositol phospholipid hydrolysis in guinea pig brain. J Neurochem 1985; 45: 1085-95.
13. Freedman SB, Harley EA, Iversen LL. Biochemical measurement of muscarinic receptor efficacy and its role in receptor regulation. Trends Pharmacol Sci 1988; 3: 54-60.
14. Wallace MA, Claro E. Comparison of serotonergic to muscarinic cholinergic stimulation of phosphoinositide specific phospholipase C in rat brain cortical membranes. J Pharmacol Exp Ther 1990; 255: 1296-300.
15. Lee HM, Tsai KJ, Lin CH, Huang CL, Tung CS. Arecoline desensitizes carbachol-stimulated phosphatidylinositol breakdown in rat brain cortices. J Neurochem 1998; 70: 1189-98.
16. 2-muscarinic receptor. Chin J Physiol 2000; 43: 23-8.
17. Porsius AJ, Coilffert B, Lambsecht G, Moser CI, Mutschler E. Muscarinic effects of various isoarecaidine esters in sympathetic ganglia. J Auton Pharmacol 1981; 1: 119-26.
18. Polinsky RT, Brown RT, Curras MT, Baser SM, Baucom CE, Hooper DR, et al. Central and peripheral effects of arecoline in patients with autonomic failure. J Neurol Neurosurg Psychiatry 1991; 54: 807-12.
19. Chu NS. Effects of betel chewing on the central and autonomic nervous systems. J Biomed Sci 2001; 8: 229-36.
20. Wakade AR. Studies on secretion of catecholamines evoked by acetylcholine or transmural stimulation of the rat adrenal gland. J Physiol 1981; 313: 463-80.
21. Anton AH, Sayre DF. A study of the factors affecting the aluminum oxidetrihydroxy indole procedure for the analysis of catecholamines. J Pharmacol Exp Ther 1962; 138: 360-75.
22. Tallarida RJ, Murray RB. Manual of pharmacologic calculation with computer programs. 2nd ed. New York: Springer-Verlag; 1987.
23. 2 biochemical and functional characterization. Life Sci 1982; 31: 2992-8.
24. Garcia AG, Sala F, Reig JA, Viniegra S, Prias J, Fonteriz R, et al. Dihydropyridine Bay-K-8644 activates chromaffin cell calcium channels. Nature 1984; 309: 69-71.
25. Lim DY, Kim CD, Ahn KW. Influence of TMB-8 on secretion of catecholamines from the perfused rat adrenal glands. Arch Pharm Res 1992; 15: 115-25.
26. 2+ permeability. Biochem Pharmacol 1989; 38: 3995-4003.
27. 2+-ATPase of sarcoplasmic reticulum. J Biol Chem 1989; 264: 17816-23.
28. Molinengo L, Orsetti M. Dose versus survival time curves in the elevation of "prompt" and "delayed" acute toxicities. J Pharm Pharmacol 1986; 38: 54-6.
29. Cena V, Nicolas GP, Sanchez-Garcia P, Kirpekar SM, Garcia AG. Pharmacological dissection of receptor-associated and voltage-sensitive ionic channels involved in catecholamine release. Neuroscience 1983; 10: 1455-62.
30. Boarder MR, Marriott D, Adams M. Stimulus secretion coupling in cultured chromaffin cells, dependency on external sodium and on dihydropyridine-sensitive calcium channels. Biochem Pharmacol 1987; 36: 163-7.
31. Owen PJ, Marriott DB, Boarder MR. Evidence for a dihydropyridine- sensitive and conotoxin-insensitive release of noradrenaline and uptake of calcium in adrenal chromaffin cells. Br J Pharmacol 1989; 97: 133-8.
32. Lopez MG, Fonteriz R, Gandia L, De la Fuente M, Villarroya M, Garcia-Sancho J, et al. The nicotinic acetylcholine receptor of the bovine chromaffin cell, a new target for dihydro-pyridines. Eur J Pharmacol Mol Biol 1993; 247: 199-207.
33. O'Farrell N, Zigas J, Marley PD. Effect of N- and L-type calcium channel antagonists and (t)-Bay-K-8644 on nerve-induced catecholamine secretion from bovine perfused adrenal glands. Br J Pharmacol 1997; 121: 381-8.
34. + currents in guinea-pig smooth muscle cells. Br J Pharmacol 1992; 107: 134-40.
35. Wakade AR, Wakade TD. Contribution of nicotinic and muscarinic receptors in the secretion of catecholamines evoked by endogenous and exogenous acetylcholine. Neuroscience 1983; 10: 973-8.